Utama › Sindrom Mielodisplastik › Minnesota
Kajian klinikal Sindrom Mielodisplastik di Minnesota
13 kajian untuk Sindrom Mielodisplastik sedang mencari peserta di lokasi di Minnesota.
Bandar di Minnesota
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- dan 5 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- dan 8 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Mayo Clinic Rochester, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT05320198The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 75 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT05805605A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT03017820MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Umur 2 hingga 75 · Semua jantina · Dikemas kini 16 Apr 2026 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Apr 2026 · NCT05732103Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
Mengambil pesertaFasa 2
Sehingga umur 65 · Semua jantina · Dikemas kini 30 Jan 2026 · NCT03579875SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Okt 2025 · NCT06712810Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- University of Minnesota, Minneapolis
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2025 · NCT06462365Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.